DexCom Q1 Beats EPS Guidance Misses

DexCom reported Q1 FY2026 adjusted EPS $0.56, beating consensus $0.47, with revenue $1.19 bn up 15% YoY.
U.S. revenue rose 11% YoY, while international revenue grew 26% reported (17% organic), supporting margin expansion.
Despite results, shares fell 5.9% as full‑year revenue guidance of $5.16‑5.25 bn missed consensus $5.226 bn.
Company raised FY2026 adjusted operating margin to 23‑23.5% and EBITDA margin to 31‑31.5%, keeping gross profit margin near 63‑64%.